Kunal C Kadakia1, Charles L Loprinzi2, Pamela J Atherton3, Kelliann C Fee-Schroeder4, Amit Sood5, Debra L Barton6. 1. Division of Hematology and Medical Oncology, University of Michigan, Ann Arbor, USA. kkadakia@umich.edu. 2. Division of Medical Oncology, Mayo Clinic, Rochester, USA. cloprinzi@mayo.edu. 3. Division of Medical Oncology, Mayo Clinic, Rochester, USA. atherton.pamela@mayo.edu. 4. Division of Medical Oncology, Mayo Clinic, Rochester, USA. feeschroeder.kelliann@mayo.edu. 5. Division of General Internal Medicine, Mayo Clinic, Rochester, USA. Sood.Amit@mayo.edu. 6. School of Nursing, University of Michigan, 400 N. Ingalls, Room 2153, Ann Arbor, MI, 48109, USA. debbartn@umich.edu.
Abstract
PURPOSE: Hot flashes are a significant source of symptom burden that negatively impacts quality of life (QOL). For women who have contraindications to, or are unwilling to consider, estrogens or antidepressants for bothersome hot flashes, there are limited effective pharmacologic or complementary and alternative medicines. METHODS: This single-arm phase II trial studied the efficacy of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. Eligible women were required to have reported ≥14 hot flashes per week for ≥1 month. The patients were treated with SAMe at a dose of 400 mg twice daily to evaluate whether a reduction in hot flash score appeared to be better than the historical placebo response of approximately 25%. The women kept a daily hot flash diary during a baseline week and then daily during weeks 2-7. The primary endpoint was the change from baseline to week 7 in hot flash score and hot flash frequency. Secondary endpoints included toxicity analyses and the effect of SAMe on QOL. RESULTS: From October 28, 2010 to January 30, 2012, 43 women were treated with SAMe. The decrease in mean percent of baseline hot flash score and frequency was 35.4 and 32.6%, respectively. When compared to the historical placebo response of 25%, the effect of SAMe on hot flash score was not statistically significant (p = 0.09). Treatment was well tolerated with expected grade 1/2 gastrointestinal toxicity and no negative effect on QOL. CONCLUSIONS: The use of SAMe does not appear to significantly reduce hot flashes more than would be expected with a placebo.
PURPOSE:Hot flashes are a significant source of symptom burden that negatively impacts quality of life (QOL). For women who have contraindications to, or are unwilling to consider, estrogens or antidepressants for bothersome hot flashes, there are limited effective pharmacologic or complementary and alternative medicines. METHODS: This single-arm phase II trial studied the efficacy of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes. Eligible women were required to have reported ≥14 hot flashes per week for ≥1 month. The patients were treated with SAMe at a dose of 400 mg twice daily to evaluate whether a reduction in hot flash score appeared to be better than the historical placebo response of approximately 25%. The women kept a daily hot flash diary during a baseline week and then daily during weeks 2-7. The primary endpoint was the change from baseline to week 7 in hot flash score and hot flash frequency. Secondary endpoints included toxicity analyses and the effect of SAMe on QOL. RESULTS: From October 28, 2010 to January 30, 2012, 43 women were treated with SAMe. The decrease in mean percent of baseline hot flash score and frequency was 35.4 and 32.6%, respectively. When compared to the historical placebo response of 25%, the effect of SAMe on hot flash score was not statistically significant (p = 0.09). Treatment was well tolerated with expected grade 1/2 gastrointestinal toxicity and no negative effect on QOL. CONCLUSIONS: The use of SAMe does not appear to significantly reduce hot flashes more than would be expected with a placebo.
Entities:
Keywords:
Clinical trials; Hot flashes; Quality of life; S-Adenosyl-L-methionine; SAMe
Authors: T Bottiglieri; M Laundy; R Martin; M W Carney; H Nissenbaum; B K Toone; A L Johnson; E H Reynolds Journal: Lancet Date: 1984-07-28 Impact factor: 79.321
Authors: Debra L Barton; Beth I LaVasseur; Jeff A Sloan; Allen N Stawis; Kathleen A Flynn; Missy Dyar; David B Johnson; Pamela J Atherton; Brent Diekmann; Charles L Loprinzi Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: C L Loprinzi; J C Michalak; S K Quella; J R O'Fallon; A K Hatfield; R A Nelimark; A M Dose; T Fischer; C Johnson; N E Klatt Journal: N Engl J Med Date: 1994-08-11 Impact factor: 91.245
Authors: Debra L Barton; Charles L Loprinzi; Pamela Atherton; Jane Raymond; Tait Shanafelt; Stephanie Hines; Fran Palmieri; Teresa Rummans; Alex A Adjei; Jeff Sloan Journal: Support Cancer Ther Date: 2007-09-01
Authors: Ellen W Freeman; Katherine A Guthrie; Bette Caan; Barbara Sternfeld; Lee S Cohen; Hadine Joffe; Janet S Carpenter; Garnet L Anderson; Joseph C Larson; Kristine E Ensrud; Susan D Reed; Katherine M Newton; Sheryl Sherman; Mary D Sammel; Andrea Z LaCroix Journal: JAMA Date: 2011-01-19 Impact factor: 157.335